Abstract
Two types of chemotherapy used in the treatment of patients with malignant glioma are carboplatin and Gliadel® wafer [(3.85% 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)]. To date there have been no published data examining their concurrent use in this disease. The purpose of this study was to evaluate combination chemotherapy with Gliadel wafer and carboplatin in patients with high-grade, malignant glioma. In this prospective phase I study, 16 patients underwent surgery, Gliadel wafer implantation (up to 8 wafers), intravenous carboplatin given postoperatively (day 3 or 4) at a dose escalation range of area under the curve (AUC)=2–6, and external beam radiation. Median age was 55 years (range 27–66 years). Fourteen (88%) patients had glioblastoma multiforme and 2 (12%) had anaplastic astrocytoma. Performance status was as follows: Eastern Cooperative Oncology Group (ECOG)=0 (2 patients), ECOG=1 (13 patients), and ECOG=2 (2 patients). Three patients were treated at each dosing level (AUC=2–6), and 4 patients were treated at an AUC=5. Carboplatin was administered to all patients by postoperative day 4. Radiation was begun on day 14–36. No grade 3 or 4 toxicities were noted in this study. Median progression-free and overall survival was 266 and 679 days, respectively. We conclude that administering systemic carboplatin is safe and well tolerated in the postoperative period immediately following resection and implantation of Gliadel wafer for the treatment of malignant glioma. Further evaluation in a phase II setting, at maximal carboplatin dose to establish potential efficacy, with this combination is warranted.
Similar content being viewed by others
References
E Galanis JC Buckner (2000) ArticleTitleChemotherapy of brain tumors Curr Opin Neurol 13 619–625 Occurrence Handle10.1097/00019052-200012000-00002 Occurrence Handle1:STN:280:DC%2BD3M7jtVyltg%3D%3D Occurrence Handle11148660
LM DeAngelis PC Burger SB Green JG Cairncross (1998) ArticleTitleMalignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 44 691–695 Occurrence Handle10.1002/ana.410440418 Occurrence Handle1:STN:280:DyaK1cvkvFOhsg%3D%3D Occurrence Handle9778271
HA Fine KB Dear JS Loeffler PM Black GP Canellos (1993) ArticleTitleMeta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 2585–2597
Medical Research Council Brain Tumor Working Party: Randomized trial of Procarbazine, Lomustine, and Vincristing in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. J Clin Oncol 19: 509–518, 2001
K Wante E Hannisdal O Nome B Hager H Hirschberg (1992) ArticleTitleCombined intra-arterial and systemic chemotherapy for recurrent malignant gliomas Neurosurgery 30 223–228 Occurrence Handle1312230
WR Shapiro SB Green PC Burger RG Selker JC VanGilder JT Robertson J Mealey SuffixJr. J Ransohff MS Mahaley SuffixJr (1992) ArticleTitleA randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma J Neurosurg 76 772–781 Occurrence Handle1:STN:280:By2B38not1Y%3D Occurrence Handle1564540
E Bouffet F Khelfaoui I Philip P Biron M Brunat-Mentigny T Philip (1997) ArticleTitleHigh-dose carmustine for high-grade gliomas in childhood Cancer Chemother Pharmacol 39 376–379 Occurrence Handle10.1007/s002800050586 Occurrence Handle1:STN:280:ByiC2sfjvVM%3D Occurrence Handle9025780
LK Fung MG Ewend A Sills EP Sipos R Thompson M Watts OM Colvin H Brem WM Saltzman (1998) ArticleTitlePharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain Cancer Res 58 672–684
CC Wang J Li CS Teo T Lee (1999) ArticleTitleThe delivery of BCNU to brain tumors J Control Release 61 21–41 Occurrence Handle10.1016/S0168-3659(99)00098-X Occurrence Handle1:CAS:528:DyaK1MXlsFOku74%3D Occurrence Handle10469900
H Brem S Piantadosi PC Burger M Walker R Selker NA Vick K Black M Sisti S Brem G Mohr et al. (1995) ArticleTitlePlacebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet 345 1008–1012 Occurrence Handle1:STN:280:ByqB2c%2FisVU%3D Occurrence Handle7723496
S Valtonen U Timonen P Toivanen H Kalimo L Kivipelto O Heiskanen G Unsgaard T Kuurne (1997) ArticleTitleInterstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study Neurosurgery 41 44–48 Occurrence Handle1:STN:280:ByiA287ktVQ%3D Occurrence Handle9218294
M Westphal DC Hilt E Bortey P Delavault R Olivares PC Warnke IR Whittle J Jaaskelainen Z Ram (2003) ArticleTitleA phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-oncol 5 79–88 Occurrence Handle1:CAS:528:DC%2BD3sXjtVKltL4%3D Occurrence Handle12672279
MG Ewend H Brem M Gilbert R Goodkin P Penar (2000) ArticleTitleSafety of treating brain metastases with surgery, BCNU-polymer wafers, and radiation therapy: phase I-II trial Neuro-oncol 2 260
S Gururangan L Cokgor JN Rich S Edwards ML Affronti JA Quinn JEII Herndon JM Provenzale RE McLendon S Tourt-Uhlig JH Sampson V Stafford-Fox S Zaknoen M Early AH Friedman HS Friedman (2001) ArticleTitlePhase I study of Gliadel® wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas Neuro-Oncol 3 246–250 Occurrence Handle10.1215/S1522851700000703 Occurrence Handle1:CAS:528:DC%2BD38Xks1Olsrs%3D Occurrence Handle11584894
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Limentani, S.A., Asher, A., Heafner, M. et al. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol 72, 241–244 (2005). https://doi.org/10.1007/s11060-004-2339-1
Issue Date:
DOI: https://doi.org/10.1007/s11060-004-2339-1